Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study).
about
Current Research Therapeutic Strategies for Alzheimer's Disease TreatmentNew Drugs from Marine Organisms in Alzheimer's DiseaseFluid Biomarkers in Clinical Trials of Alzheimer's Disease TherapeuticsThe Role of Information and Communication Technologies in Clinical Trials with Patients with Alzheimer's Disease and Related DisordersAlzheimer's disease: Unique markers for diagnosis & new treatment modalitiesTaurine in drinking water recovers learning and memory in the adult APP/PS1 mouse model of Alzheimer's diseaseThe amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy.Imaging endpoints for clinical trials in Alzheimer's disease.An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice.Drug candidates in clinical trials for Alzheimer's disease.Current and emerging drug treatment options for Alzheimer's disease: a systematic review.Amyloidosis of the head and neck: a clinicopathological study of cases with long-term follow-up.A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease-experimental approach and therapeutic implications.Homotaurine in Parkinson's disease.Role of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's disease modifying therapiesAdvances in recent patent and clinical trial drug development for Alzheimer's disease.Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD).The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives.Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines.Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.Treatment of Alzheimer's Disease: Current Management and Experimental Therapeutics.Alzheimer disease therapy--moving from amyloid-β to tau.Advances in drug design based on the amino Acid approach: taurine analogues for the treatment of CNS diseases.GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer's disease.Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's diseaseNatural products from marine organisms with neuroprotective activity in the experimental models of Alzheimer's disease, Parkinson's disease and ischemic brain stroke: their molecular targets and action mechanisms.β-Amyloid peptides and amyloid plaques in Alzheimer's disease.Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments - an update for clinicians.Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives.Homotaurine Effects on Hippocampal Volume Loss and Episodic Memory in Amnestic Mild Cognitive Impairment.Homotaurine induces measurable changes of short latency afferent inhibition in a group of mild cognitive impairment individuals.How Do Scores on the ADAS-Cog, MMSE, and CDR-SOB Correspond?Amyloid β-peptide 25-35 self-assembly and its inhibition: a model undecapeptide system to gain atomistic and secondary structure details of the Alzheimer's disease process and treatment.Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease.Cytoprotective Effects of Citicoline and Homotaurine against Glutamate and High Glucose Neurotoxicity in Primary Cultured Retinal Cells.Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
P2860
Q26765530-1CA7AD8D-F823-44B2-AEAD-1B43F3F359D2Q26771804-DE285825-6535-41B6-908A-143EA2F72F06Q26784569-EC7D9C53-00E4-4328-8783-363949FEAED5Q28082098-D9D7D742-516A-423A-888B-F66D6F06EF76Q28085139-23D78F25-6CC4-47AD-8E72-F9F308357458Q28649926-F1DCDAE9-83CA-4CEB-A842-309C6EC0C3A3Q30668465-2A2ACD2D-E8D2-4EFB-A4BB-2FC64CFFBB5CQ30885979-CF77115C-A493-4090-B029-0CA42A5DC4A0Q33626081-B6D7C960-643C-4309-BC42-4986A9F68F54Q33916749-3E05BBF1-6E65-483F-94E4-0A48051ED58BQ34222721-2CA9EE6E-A622-47DB-9A88-E3E8838FA928Q34247202-06C28204-18BF-4886-BD19-AC3E5A14C10AQ34376103-479417B5-ABC4-4A06-AEFE-B00EC19FEA5CQ34408888-F3EE086B-A9C6-4EDA-98BB-74D3BDAB3D9EQ34412322-47DEA284-5E33-4C94-BF24-428F61B33BCBQ34669429-93C1E4ED-D438-4C9B-B415-089F6D70CF50Q34974167-D7FF5A54-457D-4524-BCDB-DC9BA367F5EDQ35738142-C08E84E6-24C4-49F9-A966-756E761F651AQ36103515-0BF74943-3D38-48C4-8ED3-25D6F57AE38AQ37656554-8D78E9E3-363B-4865-9702-737682EE3649Q38022265-4C8395A3-3658-4FA2-A148-EFC4D603A66DQ38086651-154E41DD-1764-4D06-AED6-71BDA9D77E10Q38097932-ACBDF934-0B98-4270-A831-DCB1CDB5DAF9Q38127470-9A663CC8-5094-45C2-BDD0-013095FF7F0EQ38149130-7B6FA0E0-E770-4453-A577-2B8795CF561FQ38161786-0EC1E274-F768-4257-A68E-7B016F8A503AQ38166594-7E27302E-4858-47A5-A9AF-375294D57C94Q38225536-872720FE-A147-459A-86EA-6DE850CE5BD5Q38230386-A43569F2-A5DE-4433-A6BC-B06626A28280Q38263124-AEEDCA17-2897-4CE4-905C-2A74E693EFE5Q38265124-0CD00730-3235-4338-A565-82DA01A46CC4Q38269095-161A6CA5-12B0-4AF2-B2FC-DCDB69A9604BQ38719665-F41610C6-2987-4C22-8629-8D36CE6DA0BBQ38921884-09523F5A-3990-4EEA-B312-DA9C81163A2EQ39200071-07111C22-0699-46E9-BCDA-BE8C44A25711Q40263591-3B48DF2B-C01D-4698-963C-F716432CFE94Q41664110-E4F6FC5E-9CB2-4A6B-A1E4-74D593242BFAQ42689720-B6AB7401-AEE0-49B7-A2A6-76814B330D2DQ47147969-05106E8C-F80E-4BB7-B5B8-7813D8C2DBE0Q47600734-203C6AC8-AE54-4C34-BCA7-A529845CEFBE
P2860
Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study).
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Tramiprosate in mild-to-modera ...... tre study (the Alphase Study).
@ast
Tramiprosate in mild-to-modera ...... tre study (the Alphase Study).
@en
Tramiprosate in mild-to-modera ...... tre study (the Alphase Study).
@nl
type
label
Tramiprosate in mild-to-modera ...... tre study (the Alphase Study).
@ast
Tramiprosate in mild-to-modera ...... tre study (the Alphase Study).
@en
Tramiprosate in mild-to-modera ...... tre study (the Alphase Study).
@nl
prefLabel
Tramiprosate in mild-to-modera ...... tre study (the Alphase Study).
@ast
Tramiprosate in mild-to-modera ...... tre study (the Alphase Study).
@en
Tramiprosate in mild-to-modera ...... tre study (the Alphase Study).
@nl
P2093
P2860
P50
P356
P1476
Tramiprosate in mild-to-modera ...... tre study (the Alphase Study).
@en
P2093
Daniel Saumier
Denis Garceau
John Sampalis
Joyce Suhy
Serge Gauthier
P2860
P304
P356
10.5114/AOMS.2011.20612
P577
2011-02-01T00:00:00Z